Imunon Company Description

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.

The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.

Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.

The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.

The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon, Inc.

Country	United States
Founded	1982
Industry	Biotechnology
Sector	Healthcare
Employees	25
CEO	Stacy Lindborg

Contact Details

Address: 997 Lenox Drive Lawrenceville, New Jersey 08648 United States
Phone	609 896 9100
Website	imunon.com

Stock Details

Ticker Symbol	0HUZ
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US15117N7012
SIC Code	2836

Key Executives

Name	Position
Michael H. Tardugno	Executive Chairman, President and Chief Executive Officer
Jeffrey W. Church CPA, CPA	Chief Financial Officer, Executive Vice President and Corporate Secretary
Dr. Khursheed Anwer M.B.A., Ph.D.	Executive Vice President and Chief Scientific Officer
Dr. Nicholas Borys	Executive Vice President and Chief Medical Officer
Timothy J. Tumminello	Chief Accounting Officer and Controller
Marianne M. Lambertson	Vice President of Communications and Investor Relations